{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:24:27Z","timestamp":1762352667065,"version":"3.37.3"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1124\/jpet.118.248351","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T13:56:53Z","timestamp":1522763813000},"page":"624-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression"],"prefix":"10.1016","volume":"365","author":[{"given":"Xiangqing","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinli","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KeWei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.248351_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.steroids.2015.05.010","article-title":"Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice","volume":"101","author":"Ali","year":"2015","journal-title":"Steroids"},{"key":"10.1124\/jpet.118.248351_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability","volume":"58","author":"Anderson","year":"2000","journal-title":"J Affect Disord"},{"key":"10.1124\/jpet.118.248351_bib3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-005-0087-3","article-title":"Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties","volume":"182","author":"Artaiz","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.118.248351_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12035-013-8472-0","article-title":"Regulating prefrontal cortex activation: an emerging role for the 5-HT2A serotonin receptor in the modulation of emotion-based actions?","volume":"48","author":"Aznar","year":"2013","journal-title":"Mol Neurobiol"},{"key":"10.1124\/jpet.118.248351_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1176\/ajp.2006.163.9.1580","article-title":"Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907","volume":"163","author":"Bhagwagar","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2009.01.015","article-title":"Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation","volume":"19","author":"Blier","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.118.248351_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4088\/JCP.v60n0110","article-title":"Mirtazapine augmentation in the treatment of refractory depression","volume":"60","author":"Carpenter","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YCO.0b013e32831be9ef","article-title":"Augmentation strategies for treatment-resistant depression","volume":"22","author":"Carvalho","year":"2009","journal-title":"Curr Opin Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.118.248351_bib12","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/jm400408r","article-title":"Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics","volume":"56","author":"Chen","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.118.248351_bib13","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.118.248351_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.118.248351_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/026988119701100303","article-title":"Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice","volume":"11","author":"Da-Rocha","year":"1997","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2165\/00003495-199753040-00006","article-title":"Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression","volume":"53","author":"Davis","year":"1997","journal-title":"Drugs"},{"key":"10.1124\/jpet.118.248351_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00221-013-3701-3","article-title":"Serotonin in the pathophysiology and treatment of CNS disorders","volume":"230","author":"Di Giovanni","year":"2013","journal-title":"Exp Brain Res"},{"key":"10.1124\/jpet.118.248351_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2007.05.008","article-title":"Antidepressant-like effect of hyperfoliatin, a polyisoprenylated phloroglucinol derivative from Hypericum perfoliatum (Clusiaceae) is associated with an inhibition of neuronal monoamines uptake","volume":"569","author":"do Rego","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1021\/ml400049p","article-title":"Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor","volume":"4","author":"Dreyfus","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.118.248351_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"10.1124\/jpet.118.248351_bib22","first-page":"53","article-title":"Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction","volume":"57","author":"Feiger","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib23","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/0269881198012003041","article-title":"Selective serotonin reuptake inhibitors in the treatment of affective disorders\u2014III. Tolerability, safety and pharmacoeconomics","volume":"12","author":"Goldstein","year":"1998","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib24","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/0269881198012003031","article-title":"Selective serotonin reuptake inhibitors in affective disorders\u2014II. Efficacy and quality of life","volume":"12","author":"Goodnick","year":"1998","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1527-3458.2002.tb00234.x","article-title":"Duloxetine pharmacology: profile of a dual monoamine modulator","volume":"8","author":"Karpa","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1124\/jpet.118.248351_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/NDT.S39544","article-title":"New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder","volume":"10","author":"Katona","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1124\/jpet.118.248351_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbr.2015.12.008","article-title":"Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect in the forced swimming test in adrenocorticotropic hormone-treated rats","volume":"302","author":"Kawaura","year":"2016","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.118.248351_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.genhosppsych.2014.10.010","article-title":"Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial","volume":"37","author":"Khazaie","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pbb.2007.12.015","article-title":"Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors?","volume":"89","author":"Kitamura","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.118.248351_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0091-3057(01)00625-6","article-title":"Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test","volume":"71","author":"Kitamura","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.118.248351_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0091-3057(01)00769-9","article-title":"Effects of imipramine and lithium on wet-dog shakes mediated by the 5-HT2A receptor in ACTH-treated rats","volume":"72","author":"Kitamura","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.118.248351_bib32","first-page":"93","article-title":"[Development of animal models of treatment-resistant depression in rats]","volume":"28","author":"Kitamura","year":"2008","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"10.1124\/jpet.118.248351_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.118.248351_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02245281","article-title":"Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors","volume":"108","author":"Kuroda","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.118.248351_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.11.009","article-title":"Repeated electroconvulsive stimuli increase brain-derived neurotrophic factor in ACTH-treated rats","volume":"529","author":"Li","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib36","first-page":"167","article-title":"Treatment-resistant depression","volume":"80","author":"Little","year":"2009","journal-title":"Am Fam Physician"},{"doi-asserted-by":"crossref","unstructured":"Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A and Barbui C (2013) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev (7):CD004185.","key":"10.1124\/jpet.118.248351_bib37","DOI":"10.1002\/14651858.CD004185.pub3"},{"key":"10.1124\/jpet.118.248351_bib38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/da.20540","article-title":"Treatment-resistant depression: recent developments and future directions","volume":"25","author":"Mathew","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1124\/jpet.118.248351_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.amepre.2005.02.009","article-title":"Assessing the burden of disease in the United States using disability-adjusted life years","volume":"28","author":"McKenna","year":"2005","journal-title":"Am J Prev Med"},{"key":"10.1124\/jpet.118.248351_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.118.248351_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/YIC.0b013e3282eff7e0","article-title":"Which antidepressants have demonstrated superior efficacy? A review of the evidence","volume":"22","author":"Montgomery","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.neuropharm.2014.08.009","article-title":"Evaluation of 5-HT2A and mGlu2\/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment","volume":"86","author":"Muguruza","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.118.248351_bib43","first-page":"121","article-title":"Response to steroid suppression in major depression resistant to antidepressant therapy","volume":"11","author":"Murphy","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib44","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1021\/jm0309349","article-title":"Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters","volume":"46","author":"Orjales","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.118.248351_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4088\/JCP.v60n0410","article-title":"Risperidone augmentation of selective serotonin reuptake inhibitors in major depression","volume":"60","author":"Ostroff","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib46","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","article-title":"Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites","volume":"283","author":"Owens","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.248351_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jad.2015.08.073","article-title":"Duloxetine enters the brain - but why is it not found in the cerebrospinal fluid","volume":"189","author":"Paulzen","year":"2016","journal-title":"J Affect Disord"},{"key":"10.1124\/jpet.118.248351_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2014.07.044","article-title":"Treatment of cognitive dysfunction in major depressive disorder\u2014a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine","volume":"753","author":"Pehrson","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib50","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1124\/jpet.118.248351_bib51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0269881109348161","article-title":"The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target?","volume":"24","author":"Rajkumar","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.118.248351_bib52","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1517\/14656566.2012.721776","article-title":"Evidence for the use of vilazodone in the treatment of major depressive disorder","volume":"13","author":"Reinhold","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/jpet.118.248351_bib53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0925-4927(00)00076-7","article-title":"Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims","volume":"99","author":"Rosel","year":"2000","journal-title":"Psychiatry Res"},{"year":"2008","author":"Roth","series-title":"Assay Protocol Book. National Institute of Mental Health Psychoactive Drug Screening Program","key":"10.1124\/jpet.118.248351_bib54"},{"key":"10.1124\/jpet.118.248351_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0006-3223(98)00092-4","article-title":"Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder","volume":"44","author":"Rush","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-4159.2010.06947.x","article-title":"Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex","volume":"115","author":"Si","year":"2010","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.118.248351_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/ac202794q","article-title":"In vivo neurochemical monitoring using benzoyl chloride derivatization and liquid chromatography-mass spectrometry","volume":"84","author":"Song","year":"2012","journal-title":"Anal Chem"},{"key":"10.1124\/jpet.118.248351_bib59","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/15622975.2011.590225","article-title":"Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study","volume":"12","author":"Souery","year":"2011","journal-title":"World J Biol Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2017.09.003","article-title":"Characterization of the adrenocorticotrophic hormone-induced mouse model of resistance to antidepressant drug treatment","volume":"161","author":"Srikumar","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.118.248351_bib61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.118.248351_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-2999(97)01126-6","article-title":"Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats","volume":"333","author":"Takao","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.118.248351_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib64","first-page":"55","article-title":"Mirtazapine for treatment-resistant depression: a preliminary report","volume":"28","author":"Wan","year":"2003","journal-title":"J Psychiatry Neurosci"},{"key":"10.1124\/jpet.118.248351_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ardp.201300238","article-title":"Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants","volume":"347","author":"Wang","year":"2014","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1124\/jpet.118.248351_bib66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1124\/jpet.118.248351_bib67","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"10.1124\/jpet.118.248351_bib68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF00187257","article-title":"Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant","volume":"93","author":"Willner","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.118.248351_bib69","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1176\/ajp.150.5.810","article-title":"Ketoconazole administration in hypercortisolemic depression","volume":"150","author":"Wolkowitz","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.118.248351_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.1993.4","article-title":"LY248686, a new inhibitor of serotonin and norepinephrine uptake","volume":"8","author":"Wong","year":"1993","journal-title":"Neuropsychopharmacology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.248351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:05:37Z","timestamp":1739995537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524268038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0022356524268038"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.248351","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.248351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}